Chromone–lipoic acid conjugate: Neuroprotective agent having acceptable butyrylcholinesterase inhibition, antioxidant and copper-chelation activities
- 9 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in DARU Journal of Pharmaceutical Sciences
- Vol. 29 (1), 23-38
- https://doi.org/10.1007/s40199-020-00378-1
Abstract
Purpose Alzheimer’s disease (AD) is a multifaceted neurodegenerative disease. To target simultaneously multiple pathological processes involved in AD, natural-origin compounds with unique characteristics are promising scaffolds to develop novel multi-target compounds in the treatment of different neurodegenerative disease, especially AD. In this study, novel chromone-lipoic acid hybrids were prepared to find a new multifunctional lead structure for the treatment of AD. Methods Chromone-lipoic acid hybrids were prepared through click reaction and their neuroprotection and anticholinesterase activity were fully evaluated. The anti-amyloid aggregation, antioxidant and metal-chelation activities of the best compound were also investigated by standard methods to find a new multi-functional agent against AD. Results The primary biological screening demonstrated that all compounds had significant neuroprotection activity against H2O2-induced cell damage in PC12 cells. Compound 19 as the most potent butyrylcholinesterase (BuChE) inhibitor (IC50 = 7.55 μM) having significant neuroprotection activity as level as reference drug was selected for further biological evaluations. Docking and kinetic studies revealed non-competitive mixed-type inhibition of BuChE by compound 19. It could significantly reduce formation of the intracellular reactive oxygen species (ROS) and showed excellent reducing power (85.57 mM Fe+2), comparable with quercetin and lipoic acid. It could also moderately inhibit Aβ aggregation and selectively chelate with copper ions in 2:1 M ratio. Conclusion Compound 19 could be considered as a hopeful multifunctional agent for the further development gainst AD owing to the acceptable neuroprotective and anti-BuChE activity, moderate anti-Aβ aggregation activity, outstanding antioxidant activity as well as selective copper chelation ability. Graphical abstract A new chromone–lipoic acid hybrid was synthesized as anti-Alzheimer agent with BuChE inhibitory activity, anti-Aβ aggregation, metal-chelation and antioxidant properties.Keywords
Funding Information
- The National Institute for Medical Research Development (971370)
This publication has 60 references indexed in Scilit:
- Antioxidant mediated protective effect of Parthenium hysterophorus against oxidative damage using in vitro modelsBMC Complementary and Alternative Medicine, 2013
- New Tacrine–4-Oxo-4H-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Cholinergic, Antioxidant, and β-Amyloid-Reducing PropertiesJournal of Medicinal Chemistry, 2012
- Butyrylcholinesterase Is Associated With β-Amyloid Plaques in the Transgenic APPSWE/PSEN1dE9 Mouse Model of Alzheimer DiseaseJournal of Neuropathology and Experimental Neurology, 2012
- Alanine-to-threonine substitutions and amyloid diseases: Butyrylcholinesterase as a case studyChemico-Biological Interactions, 2010
- Gene therapy in Alzheimer’s disease – potential for disease modificationJournal of Cellular and Molecular Medicine, 2010
- Alzheimer's DiseaseNew England Journal of Medicine, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- The neuroprotective potential of flavonoids: a multiplicity of effectsGenes & Nutrition, 2008
- Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solutionProtein Science, 1993
- Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-onesJournal of Medicinal Chemistry, 1991